Date: July 05, 2016

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program,
Section IIA-Immunization Schedules & Section VII-Biological Products

Section IIA-Immunization Schedules

2.0 Routine Schedules

- **2.1 Schedule A & 2.2 Schedule B**
  Meningococcal C conjugate (Men-C-C) vaccine removed from Grade 6, and meningococcal quadrivalent conjugate (Men-C-ACYW-135) vaccine added to Grade 9.

- **2.3 Schedule C**
  Men-C-C scheduling guidelines revised, and Men-C-ACYW-135 added for children born on or after January 1, 2002 and who are in Grade 9 or older. The accompanying Personalized Schedule Worksheet has been revised to include Men-C-ACYW-135.

Please remove page numbers: 4-7 dated January 2016
Please add new page numbers: 4-7 dated July 2016

3.1 Minimum Intervals Between Vaccine Doses Table

- Meningococcal quadrivalent conjugate vaccines Menveo® and Menactra® added to the table, with associated footnote ‘I’ relating to the recommended interval between any meningococcal C conjugate vaccine and meningococccal quadrivalent conjugate vaccine being 4 weeks (regardless of which vaccine is given first).

- Footnote ‘H’ for Men-C-C vaccine revised and content added indicating that NEISVAC-C® is the recommended and supplied product for the primary infant series, however any meningococcal C conjugate vaccine may be used for doses given at 18 months of age or older.

Please remove page numbers: 12 & 13 dated January 2016
Please add new page numbers: 12 & 13 dated July 2016
Section VII-Biological Products

Meningococcal C Conjugate (MCC) Vaccine

- INDICATIONS updated to remove Grade 6 students, and the following eligibility revised to indicate:
  - Children who have not received a dose of Men-C-C vaccine after 12 months of age, and who are younger than Grade 9.
  - Adolescents and adults born prior to January 1, 2002, who have not received a dose of Men-C-C vaccine at 10 years of age or older. (Note: a footnote for this indication includes a maximum age of 24 years to be eligible for the vaccine.)
- ADMINISTRATION updated to remove content related to Menjugate® Liquid, as BC will not be supplying this product.
- SPECIAL CONSIDERATIONS revised to indicate that NEISVAC-C® is the recommended and supplied product for the primary infant series, however any meningococcal C conjugate vaccine may be used for doses given at 18 months of age or older. Content related to the Grade 6 Men-C-C program has also been removed.

Please remove page numbers: 39 & 40 dated January 2016
Please add new page numbers: 39 & 40 dated July 2016

Meningococcal Quadrivalent Conjugate Vaccines (Groups A, C, Y, W-135)

- INDICATIONS updated to include ‘adolescents born on or after January 1, 2002 and who are in grade 9 or older’, with accompanying footnotes for more information. An additional footnote has also been added indicating that for medically high risk individuals, Men-C-ACYW-135 should be given in place of Men-C-C as part of the routine schedule and administered according to age at presentation.
- SPECIAL CONSIDERATIONS revisions include:
  - Removal of content indicating that ‘these products can be administered to people with a history of Guillain-Barre syndrome (GBS) without concern’, as this content is no longer new and information regarding GBS as a contraindication to a particular vaccine can be found in the respective vaccine product pages in Section VII-Biological Products, as well as Section IIB-Contraindications and Precautions for Immunization.
  - Removal of content indicating that ‘high risk children less than 10 years of age who have only received one dose of Men-C-ACYW-135 should also receive one dose of Men-C-C vaccine if they have not received a dose of Men-C-C vaccine after 12 months of age’.

Please remove page numbers: 41 & 42 dated August 2015
Please add new page numbers: 41 & 42 dated July 2016
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at christine.halpert@bccdc.ca

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
   Dr. Perry Kendall
   Provincial Health Officer
   
   Dr. Bonnie Henry
   Deputy Provincial Health Officer
   
   Craig Thompson
   Director of Immunization
   Healthy Populations and Development Branch
   
   Warren O’Briain
   Executive Director
   Healthy Populations and Development Branch